Effect of Dupilumab on Sleep Apnea in Patients With Rhinosinusitis

Summary

Obstructive Sleep Apnea (OSA) is a common disorder with serious consequences that remains underrecognized, with \>80% of OSA patients undiagnosed, and undertreated due to inadequate treatment options. The development of additional treatments for OSA, such as pharmacotherapy, are critically needed. The collaboration between Regeneron and Sanofi are funding this project. Regeneron will be providing the drug and the contract will be with Regeneron. Both companies are involved as it is a collaboration across the companies.

Timeline

Start

2018-08-15

Primary completion

2022-07-01

Completion

2022-07-01

Drugs

Indications